[go: up one dir, main page]

FR2873691B1 - Derives d'amino-piperidine, leur preparation et leur application en therapeutique - Google Patents

Derives d'amino-piperidine, leur preparation et leur application en therapeutique

Info

Publication number
FR2873691B1
FR2873691B1 FR0408370A FR0408370A FR2873691B1 FR 2873691 B1 FR2873691 B1 FR 2873691B1 FR 0408370 A FR0408370 A FR 0408370A FR 0408370 A FR0408370 A FR 0408370A FR 2873691 B1 FR2873691 B1 FR 2873691B1
Authority
FR
France
Prior art keywords
amino
preparation
therapeutic application
piperidine derivatives
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408370A
Other languages
English (en)
Other versions
FR2873691A1 (fr
Inventor
Alain Braun
Bruno Cornet
Gilles Courtemanche
Olivier Crespin
Eykmar Fett
Cecile Pascal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0408370A priority Critical patent/FR2873691B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to JP2007523109A priority patent/JP2008508241A/ja
Priority to KR1020077004659A priority patent/KR20070047804A/ko
Priority to BRPI0512688-6A priority patent/BRPI0512688A/pt
Priority to RU2007107375/04A priority patent/RU2376303C2/ru
Priority to MX2007001137A priority patent/MX2007001137A/es
Priority to CNA2005800292193A priority patent/CN101039941A/zh
Priority to EP05790800A priority patent/EP1786809A2/fr
Priority to CA002574454A priority patent/CA2574454A1/fr
Priority to AU2005276354A priority patent/AU2005276354A1/en
Priority to PCT/FR2005/001855 priority patent/WO2006021656A2/fr
Priority to ARP050103111A priority patent/AR050186A1/es
Priority to UY29041A priority patent/UY29041A1/es
Priority to TW094125586A priority patent/TW200621768A/zh
Priority to PE2005000890A priority patent/PE20060562A1/es
Publication of FR2873691A1 publication Critical patent/FR2873691A1/fr
Application granted granted Critical
Publication of FR2873691B1 publication Critical patent/FR2873691B1/fr
Priority to IL180766A priority patent/IL180766A/en
Priority to US11/626,972 priority patent/US20070191364A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0408370A 2004-07-29 2004-07-29 Derives d'amino-piperidine, leur preparation et leur application en therapeutique Expired - Fee Related FR2873691B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR0408370A FR2873691B1 (fr) 2004-07-29 2004-07-29 Derives d'amino-piperidine, leur preparation et leur application en therapeutique
AU2005276354A AU2005276354A1 (en) 2004-07-29 2005-07-20 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists
BRPI0512688-6A BRPI0512688A (pt) 2004-07-29 2005-07-20 derivados de amimo-piperidina, o respectivo preparo e a respectiva aplicação em terapêutica
RU2007107375/04A RU2376303C2 (ru) 2004-07-29 2005-07-20 Производные аминопиперидина, их получение и применение в терапии
MX2007001137A MX2007001137A (es) 2004-07-29 2005-07-20 Derivados de aminopiperidina, preparacion de los mismos y uso de los mismos como agonistas de receptor de melanocortina.
CNA2005800292193A CN101039941A (zh) 2004-07-29 2005-07-20 氨基哌啶衍生物及其制备方法和作为黑皮质素受体激动剂的用途
EP05790800A EP1786809A2 (fr) 2004-07-29 2005-07-20 Derives d'amino-piperidine, leur preparation et leur application en tant qu'agonistes des recepteurs aux melanocortines
CA002574454A CA2574454A1 (fr) 2004-07-29 2005-07-20 Derives d'amino- piperidine, leur preparation et leur application en therapeutique
JP2007523109A JP2008508241A (ja) 2004-07-29 2005-07-20 アミノピペリジン誘導体、その調製及びメラノコルチン受容体作用物質としてのその使用
PCT/FR2005/001855 WO2006021656A2 (fr) 2004-07-29 2005-07-20 Derives d'amino- piperidine , leur preparation et leur application en tant qu'agonistes des recepteurs aux melanocortines
KR1020077004659A KR20070047804A (ko) 2004-07-29 2005-07-20 아미노피페리딘 유도체, 이의 제조 방법, 및 이의멜라노코르틴 수용체 효능제로서의 용도
ARP050103111A AR050186A1 (es) 2004-07-29 2005-07-27 Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
UY29041A UY29041A1 (es) 2004-07-29 2005-07-28 Derivados de amino-piperidina, su preparacion y su utilización en terapeutica
TW094125586A TW200621768A (en) 2004-07-29 2005-07-28 Aminopiperidine derivatives, preparation thereof and therapeutic use thereof
PE2005000890A PE20060562A1 (es) 2004-07-29 2005-08-01 Derivados de amino-piperidina como agonistas de los receptores de melanocortina mc3 y/o mc4
IL180766A IL180766A (en) 2004-07-29 2007-01-17 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists
US11/626,972 US20070191364A1 (en) 2004-07-29 2007-01-25 Aminopiperidine derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408370A FR2873691B1 (fr) 2004-07-29 2004-07-29 Derives d'amino-piperidine, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2873691A1 FR2873691A1 (fr) 2006-02-03
FR2873691B1 true FR2873691B1 (fr) 2006-10-06

Family

ID=34949116

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408370A Expired - Fee Related FR2873691B1 (fr) 2004-07-29 2004-07-29 Derives d'amino-piperidine, leur preparation et leur application en therapeutique

Country Status (17)

Country Link
US (1) US20070191364A1 (fr)
EP (1) EP1786809A2 (fr)
JP (1) JP2008508241A (fr)
KR (1) KR20070047804A (fr)
CN (1) CN101039941A (fr)
AR (1) AR050186A1 (fr)
AU (1) AU2005276354A1 (fr)
BR (1) BRPI0512688A (fr)
CA (1) CA2574454A1 (fr)
FR (1) FR2873691B1 (fr)
IL (1) IL180766A (fr)
MX (1) MX2007001137A (fr)
PE (1) PE20060562A1 (fr)
RU (1) RU2376303C2 (fr)
TW (1) TW200621768A (fr)
UY (1) UY29041A1 (fr)
WO (1) WO2006021656A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873690B1 (fr) * 2004-07-29 2006-10-13 Sanofi Synthelabo Derives d'oxopiperidine, leur preparation et leur application en therapeutique
SI3184526T1 (sl) * 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
EP2003131A4 (fr) * 2006-04-04 2009-12-16 Taisho Pharmaceutical Co Ltd Composé d'aminopyrrolidine
MX2009013402A (es) 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
WO2010065800A1 (fr) * 2008-12-04 2010-06-10 Palatin Technologies, Inc. Composés de pipérazine spécifiques des récepteurs de la mélanocortine substitués par un hydrazine
WO2010135621A1 (fr) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak
WO2010135650A1 (fr) * 2009-05-22 2010-11-25 Incyte Corporation Dérivés de n-(hétéro)aryl-pyrrolidine de pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines et pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines en tant qu'inhibiteurs de la janus kinase
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
EP2640725B1 (fr) 2010-11-19 2015-01-07 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak
EP2721028B1 (fr) 2011-06-20 2015-11-04 Incyte Corporation Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR20130083592A (ko) * 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
EP3489239B1 (fr) 2013-03-06 2021-09-15 Incyte Holdings Corporation Procédés et intermédiaires pour fabriquer un inhibiteur de jak
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MX2020007973A (es) 2018-01-30 2020-12-07 Incyte Corp Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona).
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
JP7467510B2 (ja) 2019-11-07 2024-04-15 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
EP1187614A4 (fr) * 1999-06-04 2005-06-22 Merck & Co Inc Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
EP1268449A4 (fr) * 2000-03-23 2004-09-15 Merck & Co Inc Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
CA2438272A1 (fr) * 2001-03-02 2002-10-10 John Macor Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
TWI341835B (en) * 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
FR2873690B1 (fr) * 2004-07-29 2006-10-13 Sanofi Synthelabo Derives d'oxopiperidine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
KR20070047804A (ko) 2007-05-07
PE20060562A1 (es) 2006-07-12
JP2008508241A (ja) 2008-03-21
UY29041A1 (es) 2006-02-24
IL180766A (en) 2011-10-31
RU2376303C2 (ru) 2009-12-20
BRPI0512688A (pt) 2008-04-01
IL180766A0 (en) 2007-06-03
AR050186A1 (es) 2006-10-04
RU2007107375A (ru) 2008-09-10
CN101039941A (zh) 2007-09-19
FR2873691A1 (fr) 2006-02-03
CA2574454A1 (fr) 2006-03-02
WO2006021656A2 (fr) 2006-03-02
MX2007001137A (es) 2007-04-19
WO2006021656A3 (fr) 2006-06-08
AU2005276354A1 (en) 2006-03-02
EP1786809A2 (fr) 2007-05-23
US20070191364A1 (en) 2007-08-16
TW200621768A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
FR2873691B1 (fr) Derives d&#39;amino-piperidine, leur preparation et leur application en therapeutique
FR2854158B1 (fr) Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2864080B1 (fr) Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2872813B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
MA29017B1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2854633B1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) Derives d&#39;aryl-et d&#39;heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
MA28575B1 (fr) Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique
MA27049A1 (fr) Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2866888B1 (fr) Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2843964B1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2850377B1 (fr) Derives d&#39;arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2864958B1 (fr) Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
MA27233A1 (fr) Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
FR2866885B1 (fr) Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2865205B1 (fr) Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2856684B1 (fr) Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2873690B1 (fr) Derives d&#39;oxopiperidine, leur preparation et leur application en therapeutique
FR2885364B1 (fr) Derives d&#39;alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
FR2888847B1 (fr) Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2891828B1 (fr) Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
FR2860792B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
FR2870846B1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
FR2873693B1 (fr) Derives d&#39;amino-tropane, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20130329